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prevention. It is also worth mentioning 
that rosiglitazone treatment has recently 
been shown to cause severe side eﬀects, 
such as weight gain as seen in this study, 
ﬂuid retention, and increased cardiovas-
cular risk.9,10 Thus, it becomes impor-
tant to determine whether the beneﬁt of 
using TZDs would outweigh the risks.
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Research in HIV-related 
renal diseases lags behind 
their burden to the ‘positive’ 
community
LA Szczech1
Although outcomes for persons with HIV infection and renal disease 
have improved, the analysis by Choi et al. suggests that they remain 
similar to or worse than outcomes for persons with diabetes mellitus. 
This study should be used to frame the research resources that we 
devote to furthering knowledge in this area.
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It has been my individual perception 
that HIV-related kidney diseases were 
not and are not getting the appropriate 
quantity of dedicated clinical research, 
given the risk of morbidity and mortal-
ity associated with them. I have often 
wondered why.
In the 1980s, when the possibility 
that the HIV virus could be associated 
with the kidney disease HIV-associated 
nephropathy became apparent,1 patient 
outcomes were swift and devastating. 
The average patient was on dialysis 3 
months after the recognition of his or 
her kidney disease,2 and the mortality 
rate was a striking 50% for those who 
survived to dialysis.3–5 I remember the 
problems that we faced with graft infec-
tions among persons with HIV and even 
early discussions of whether or not it 
was appropriate to oﬀer dialysis to this 
group of patients.
The development of eﬀective antiret-
roviral medications was clearly among 
the most amazing and rapid births of 
therapeutic regimens in the history 
of modern medicine. The early 1990s 
brought the availability of eﬀective nucl-
eoside reverse transcriptase inhibitors 
and their now familiar codes of AZT, 
d4T, ddI, and so on. The mid-1990s saw 
the introduction of the ﬁrst protease 
inhibitors. The subsequent development 
of new drug classes—non-nucleoside 
reverse transcriptase inhibitors and 
fusion inhibitors—and the practice of 
combining diﬀerent drug classes into 
exceptionally eﬀective and complemen-
tary regimens (highly active antiretrovi-
ral therapy) have cumulatively improved 
outcomes at an astonishing rate.6 With 
this improvement, it is estimated that 
the relative proportion of persons with 
HIV who begin dialysis has also been 
positively aﬀected.7
So have we won the battle against 
HIV-related renal disease? Absolutely 
not. The article by Choi et al.8 (this 
issue) provides that reality check.
In this analysis of patients receiving 
their care within the Veterans Adminis-
tration Health System, Choi et al.8 dem-
onstrate that the risk of end-stage renal 
disease (ESRD) among African Ameri-
cans is twice as high in those with HIV 
infection as it is in those with diabetes 
mellitus. Given that the rate of decline 
of kidney function and the rate of death 
are also almost twice as high among 
African Americans with HIV infection 
as they are among those with diabetes, 
arguably, it is likely that a signiﬁcant 
proportion of African Americans with 
HIV and chronic kidney disease are 
dying before developing ESRD and that 
the actual risk of ESRD is therefore even 
higher than Choi et al.8 estimate.
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This is a familiar story to nephrologists. 
So why are we not alarmed? It is my the-
ory that we are comforted by the improve-
ment in outcomes since the 1990s, and we 
think that the battle is over.
We need to recognize that although 
antiretroviral therapy clearly has a ben-
eﬁcial eﬀect on kidney function among 
those with chronic kidney disease,9–11 
resulting in a decreased rate of progres-
sion of renal disease in comparison 
with the era prior to the development 
of modern eﬀective regimens,11 these 
improvements have not brought us 
where we want to be in terms of out-
comes. Outcomes are better, but simply 
improving them over the dismal begin-
nings of the early 1990s should not, 
ethically, be the only goal.
The absolute numbers of persons liv-
ing with HIV and AIDS continue to 
rise.12 Because of improved survival 
and other factors such as medication 
toxicities, the population that we are 
treating with HIV is aging and devel-
oping increasing comorbidities. HIV 
providers are now being put in the same 
position in which we as nephrologists 
often ﬁnd ourselves with our dialysis 
patients: filling the multiple roles of 
primary care provider, cardiologist, 
and endocrinologist. The complexity of 
caring for a person on multiple antiret-
rovirals is evolving so rapidly that other 
subspecialties may have diﬃculty simply 
keeping current.
The analysis by Choi et al.8 is objective 
evidence that in spite of all the improve-
ments in the antiretroviral regimens 
and the care of those with HIV, we 
as a renal community have not yet 
approached the ﬁnish line in terms of 
the care of kidney disease, particularly 
among African Americans. This analysis 
demonstrates that renal disease among 
African Americans with HIV is at 
least as frequent and aggressive as that 
among those with diabetes, if not more 
so. As nephrologists, we devote consid-
erable clinical and research energy and 
resources to the care of persons with 
diabetes. This analysis practically con-
cludes that we should be matching that 
energy in those with HIV.
Available resources for the nephrolo-
gist in the care of persons with HIV 
and kidney disease include a plethora 
of observational studies that strengthen 
our knowledge of antiretroviral medi-
cations and their beneﬁts and toxici-
ties, including the controversies over 
increased risk of Fanconi’s syndrome, 
acute renal failure, hypertension, diabe-
tes mellitus, dyslipidemias, and myocar-
dial infarction associated with speciﬁc 
agents. The observational studies and 
educational programs are almost too 
numerous to list. But we have no ran-
domized, controlled trials to allow us 
to continue the dedication to evidence-
based therapies that we value so signiﬁ-
cantly in other kidney diseases.
We have been describing the epide-
miology of HIV-related kidney diseases 
for twenty years. Isn’t it time to test a 
treatment strategy? A quick search on 
http://www.clinicaltrials.gov (on 6 
August 2007) found 51 studies when the 
search included ‘HIVAN’ or ‘HIV’ and 
‘kidney,’ of which all were observational 
and none was a treatment trial. When 
‘diabetes’ and ‘kidney’ were entered, 406 
studies were listed, of which at least half 
were treatment trials. Arguably, it would 
not be appropriate to exactly match the 
ﬁnancial dedication to research between 
the two diseases given that the absolute 
numbers of persons reaching ESRD each 
year are quite diﬀerent (220,929 persons 
with diabetes mellitus incident between 
2000 and 2004 and 4,219 persons with 
HIV incident between 2000 and 200413). 
However, the void that currently exists 
where HIV treatment trials should be 
needs to be ﬁlled to some degree.
So where is the lesion that results in 
this deﬁciency? Is it in limited availabil-
ity of treatments to test, limited interest 
among researchers, or limited funding 
priorities at the federal and industry lev-
els? Given that it is certainly not an issue 
of limited disease, I would welcome dis-
cussion of this question and vetting of 
solutions to ﬁll the gap (Figure 1).
The analysis by Choi et al.8 is note-
worthy. It is our wake-up call. Kidney 
disease among persons with HIV infec-
tion is less aggressive than it was in the 
1980s, but it still rivals our well-known 
enemy of diabetic nephropathy. Given 
our dedication as a renal community 
to attacking renal disease, particularly 
where racial disparities exist, this has 
got to be the next frontier where we 
battle it, using rigorous methodology 
and prospective trials. We have not yet 
reached the ﬁnish line in the treatment 
of kidney disease related to HIV infec-
tion, but we have clearly defined the 
race that we need to run. We can’t slow 
down now.
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The International Pediatric 
Peritonitis Registry: Starting to 
walk
I Teitelbaum1
The International Pediatric Peritonitis Registry (IPPR) was created to 
assess and evaluate the validity of the pediatric peritonitis treatment 
guidelines issued by the International Society for Peritoneal Dialysis. 
The study by Schaefer et al., one of the first to emerge from the 
IPPR, describes regional variability in the frequency of culture-
negative peritonitis and of Gram-negative infections. This analysis 
is a crucial step in the development of evidence-based treatment 
recommendations whereby to improve outcomes for the youngest 
peritoneal dialysis patients.
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The degree of utilization of peritoneal 
dialysis as renal replacement therapy in 
adults varies widely around the globe, 
ranging from as high as 40%–70% in 
New Zealand and Mexico to as low 
as 8% or less in the United States and 
Japan.1 In contrast, the utilization of 
peritoneal dialysis in pediatric patients 
is approximately 50% worldwide.2 This 
is due largely to improved quality of 
life, the ability to maintain attendance 
in school, and the ability to avoid place-
ment of percutaneous vascular access in 
small patients in whom ﬁstulae or grafts 
cannot be established. For both patient 
groups, however, infectious complica-
tions, particularly peritonitis, remain 
a major cause of peritoneal membrane 
failure and patient transfer to hemodi-
alysis (Figure 1).3 This is especially true 
of the pediatric population, in which the 
frequency of peritonitis is even greater 
than that in adults.4
The microbiologic pattern of peri-
toneal dialysis-related peritonitis in 
adults has been carefully defined in 
various parts of the world, including 
North America, Europe, Asia, and Aus-
tralia. Although there is some regional 
variability, Gram-positive organisms 
are most commonly implicated, gen-
erally accounting for 50%–65% of 
episodes; 15%–25% are due to Gram-
negative organisms, 10%–20% are 
culture-negative, and fewer than 5% are 
accounted for by fungi and mycobacte-
ria. Knowledge of this microbiologic 
pattern has enabled the International 
Society for Peritoneal Dialysis (ISPD) 
to issue informed recommendations for 
the empiric treatment of peritonitis and 
for the subsequent modiﬁcations of the 
antibiotic regimen once the organism 
has been identiﬁed. These recommen-
dations have been periodically updated 
as newer information regarding antimi-
crobial susceptibilities and other best-
practice patterns has become available; 
the most recent of these was published 
in 2005.5
In 2000 the ISPD published its ﬁrst 
set of peritonitis treatment guide-
lines designed to speciﬁcally address 
the needs of pediatric patients.6 These 
guidelines were largely opinion-based, 
as the efficacy of specific treatment 
algorithms in pediatric patients had 
never been evaluated. Furthermore, in 
contrast to adults, the microbiology of 
peritoneal dialysis-related peritonitis 
around the globe had not been deﬁned 
in the pediatric population. The Inter-
national Pediatric Peritonitis Registry 
(IPPR) was created in 2001 with the 
objective of critically assessing and eval-
uating the validity of the 2000 pediatric 
peritonitis treatment guidelines.7 An 
overall analysis of data from the IPPR 
to date — including the clinical features 
of peritonitis at presentation, antibiotic 
sensitivities, the extent of responsive-
ness to empiric treatment, and sugges-
tions for modiﬁcation of the empiric 
treatment recommendations — is being 
published elsewhere.8 Schaefer et al.9 
(this issue) report on other important 
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